This is the default image
November 1, 2016 by TAC RESEARCH WEEKLY: Hurdling the clozapine barriers

(Nov. 1, 2016) In the medicine cabinet of serious mental illness drugs, clozapine – trademarked Clozaril – occupies a number of unique positions.*  It is the only antipsychotic approved by […]

01 November 2016
This is the default image
September 29, 2016 by TAC RESEARCH WEEKLY: New research on mental illness behind bars

(Sept 29, 2016) The drumbeat of surveys, studies and statistics detailing the plight of individuals with serious mental illness in jails and prisons continued in the summer of 2016 with […]

29 September 2016
This is the default image
September 13, 2016 by TAC RESEARCH WEEKLY: Find SMI research faster, easier

(Sept 13, 2016) Evidence about how severe mental illness impacts individuals and communities is systematically under-studied, overlooked or ignored by government agencies and other organizations. Findings often are barely accessible […]

13 September 2016
This is the default image
August 31, 2016 by TAC RESEARCH WEEKLY: Clozapine by the numbers

(Aug. 31, 2016) If a “miracle drug” that reliably reduced life-threatening symptoms of heart disease and lowered treatment costs were prescribed to only 4% of the cardiac patients who would […]

31 August 2016
This is the default image
August 23, 2016 by TAC RESEARCH WEEKLY: The perilous shortage of psychiatrists

(Aug. 23, 2016) Serious mental illness (SMI) is associated with a multitude of consequences that can shorten and reduce the quality of life for those who have it. Arrest, incarceration, homelessness, […]

23 August 2016
This is the default image
August 9, 2016 by TAC RESEARCH WEEKLY: The high cost of schizophrenia

(Aug. 9, 2016) New research estimates the direct and indirect cost of schizophrenia to US society in 2013 was $155 billion – $44,773 per individual with the disease. By comparison, major […]

09 August 2016